Merck & Co., Inc. (NYSE:MRK) Shares Sold by Requisite Capital Management LLC

Requisite Capital Management LLC reduced its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 30.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,184 shares of the company’s stock after selling 956 shares during the period. Requisite Capital Management LLC’s holdings in Merck & Co., Inc. were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Ruedi Wealth Management Inc. increased its stake in Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the period. AlphaMark Advisors LLC bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $34,000. Valued Wealth Advisors LLC bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $42,000. TFO Wealth Partners LLC grew its position in Merck & Co., Inc. by 108.1% in the third quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after acquiring an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new stake in Merck & Co., Inc. in the third quarter worth approximately $50,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on MRK shares. UBS Group boosted their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $129.71.

View Our Latest Stock Analysis on MRK

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock traded down $0.64 during mid-day trading on Tuesday, reaching $130.35. 6,550,741 shares of the stock were exchanged, compared to its average volume of 8,717,681. The company has a market cap of $330.13 billion, a price-to-earnings ratio of 935.21, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89. The firm has a 50-day simple moving average of $125.24 and a 200 day simple moving average of $113.04. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. The business had revenue of $14.63 billion during the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $1.62 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.36%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is presently 2,200.00%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.